PACB - Pacific Biosciences of California, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

3.5200

-0.0300 (-0.85%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	3.5500
Open	3.5200
Bid	3.4700 x 3200
Ask	3.5300 x 1400
Day's Range	3.4700 - 3.5700
52 Week Range	2.2000 - 7.0300
Volume	1,101,664
Avg. Volume	1,811,757

Market Cap	542.319M
Beta (5Y Monthly)	1.69
PE Ratio (TTM)	N/A
EPS (TTM)	-0.3430
Earnings Date	Aug 04, 2020 - Aug 10, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Thomson Reuters StreetEvents
Edited Transcript of PACB earnings conference call or presentation 6-May-20 8:30pm GMT
Q1 2020 Pacific Biosciences of California Inc Earnings Call
Zacks
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Motley Fool
Pacific Biosciences of California Inc (PACB) Q1 2020 Earnings Call Transcript
Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or alternatively as furnished on the Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. With me today are Mike Hunkapiller, our Chief Executive Officer; Susan Barnes, our Chief Financial Officer; and Ben Gong, our Vice President of Finance and Treasurer.
GlobeNewswire
Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results
MENLO PARK, Calif., May 06, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2020. As.
Zacks
ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss
ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.
Zacks
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand
Masimo (MASI) sees solid growth in key Product segment in Q1.
Zacks
Here's Why You Should Retain Inogen (INGN) Stock for Now
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
GlobeNewswire
Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call
MENLO PARK, Calif., April 27, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial.
Zacks
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
GlobeNewswire
inqaba biotec acquires the first PacBio Sequel II System in Africa
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, and inqaba biotec, the leading commercial DNA sequencing service provider in sub-Saharan Africa, today announced the addition of a PacBio Sequel II System to inqaba biotec’s portfolio of genomics services. Based on the well-established Single Molecule, Real-Time (SMRT®) Sequencing technology, the Sequel II System offers highly accurate long reads, with 15x more data compared with the original Sequel System.
GlobeNewswire
Pacific Biosciences Powers SARS-CoV-2 Research at Commercial, Academic and Government Labs
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, academic and government research teams that are investigating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The highly accurate long reads produced by the company’s Single Molecule, Real-Time (SMRT®) Sequencing technology can be used to resolve variants of the virus that exist within one individual or across a population of patients, which is critical to developing and maintaining effective diagnostics, vaccines and medicines.
GlobeNewswire
Statement on Jury Verdict in Delaware Trial Against Oxford Nanopore Technologies
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall favorable for Pacific Biosciences, but mixed in terms of its findings. The jury declined to find valid or infringed U.S. Patent No. 9,738,929, also asserted by Pacific Biosciences in the actions. “We are disappointed with today’s verdict, which appears to be internally inconsistent regarding the validity of our patents,” said Dr. Michael W. Hunkapiller, President and Chief Executive Officer of Pacific Biosciences.
Zacks
Why Is Pacific Biosciences (PACB) Down 18.1% Since Last Earnings Report?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswire
Christian Henry Appointed Chairman of Pacific Biosciences’ Board of Directors
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors. As part of its annual review of the leadership structure of Pacific Biosciences, the Board of Directors decided to separate the Chairman and Chief Executive Officer positions in alignment with best practices. Mr. Henry will become Chairman of the Board, effective immediately and Dr. Michael Hunkapiller will continue to serve as President and Chief Executive of the Company, as well as an active member of the board.
GuruFocus.com
Larry Robbins' Top 6 4th-Quarter Buys in Health Care
Guru establishes three new health care holdings, markets continue falling on coronavirus fears Continue reading...
GlobeNewswire
Pacific Biosciences to Support Sequencing of California Species for the Earth BioGenome Project
The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of ecologically important organisms in the state of California through the EBP. The effort will be centered at the University of California, Davis.
Thomson Reuters StreetEvents
Edited Transcript of PACB earnings conference call or presentation 6-Feb-20 9:30pm GMT
Q4 2019 Pacific Biosciences of California Inc Earnings Call
GlobeNewswire
Pacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020. Mr. Phillips has directed the development of PacBio’s technology since joining the company in 2005.
Zacks
Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.
Zacks
Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Pacific Biosciences Announces Fourth Quarter and Annual 2019 Financial Results
MENLO PARK, Calif., Feb. 06, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31,.
ACCESSWIRE
Pacific Biosciences of California, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Pacific Biosciences of California, Inc. (NASDAQ:PACB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February ...
Zacks
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.